XORTX Therapeutics Inc.

NasdaqCM:XRTX Stock Report

Market Cap: US$3.6m

XORTX Therapeutics Management

Management criteria checks 4/4

XORTX Therapeutics' CEO is Allen Davidoff, appointed in Jan 2018, has a tenure of 8.5 years. total yearly compensation is $330.38K, comprised of 98.3% salary and 1.7% bonuses, including company stock and options. directly owns 1.46% of the company’s shares, worth $52.02K. The average tenure of the management team and the board of directors is 4.2 years and 4.1 years respectively.

Key information

Allen Davidoff

Chief executive officer

US$330.4k

Total compensation

CEO salary percentage98.29%
CEO tenure8.5yrs
CEO ownership1.5%
Management average tenure4.2yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 19

XORTX completes positive pre-phase 3 meeting with the FDA

XORTX Therapeutics (NASDAQ:XRTX) said it had completed the previously announced Type B Pre-phase 3 meeting with the U.S. Food and Drug Administration for XRx-008 program for the treatment of autosomal dominant polycystic kidney disease. Ahead of the meeting with the FDA, the Pre-Phase 3 Briefing Package provided an up-to-date summary of the work completed for the XRx-008 program, including updates regarding chemistry, manufacturing, pharmacology, toxicology, clinical results to date, and regulatory and clinical plans. The company said the FDA reviewed the package of data and responded with minimal comments on the work accomplished to date and focused their feedback on XORTX clinical planning. The FDA's focus of the meeting was on optimizing trial design. "A particularly valuable aspect of FDA advice was an emphasis on how the Company might gain market approval with a single phase 3 registration trial to demonstrate efficacy and safety," the company added. XORT has risen 1.5% before the bell.
Seeking Alpha • Aug 22

Xortx stock soars 40% as kidney disease drug shows promise in bridging study

Xortx Therapeutics (NASDAQ:XRTX) said its proprietary formulation of oxypurinol showed a substantial increase in oral bioavailability provided with food compared to the fasted state in a pharmacokinetics bridging study, dubbed XRX-OXY-101, Part 2. The company added that the trial also showed a clean safety and pharmacologic profile with no drug related adverse or serious adverse events related to oral administration of oxypurinol. XRX-OXY-101 bridging pharmacokinetic study is designed with four important objectives, the company noted in an Aug. 22 press release. "Successful completion of Part 1 and now part 2 of the XRX-OXY-101 study provides key data and knowledge for selecting the clinical dose and formulation for future oral dosing for our planned phase 3 registration trial in ADPKD," said Xortx CEO Allen Davidoff. The company's planned phase 3 trial in autosomal dominant polycystic kidney disease (ADPKD) expects to begin patient dosing in H1 2023. XRTX +40.40% to $2.12 premarket Aug. 22
Seeking Alpha • Jul 13

XORTX jumps over 100% after early encouraging data for rare disease therapy

Nano-cap pharma XORTX Therapeutics (NASDAQ:XRTX) surged ~103% on above average volume in the pre-market Wednesday after the company announced encouraging results for its oxypurinol formulation from a pharmacokinetics bridging study. The trial XRX-OXY-101 was the Part 1 of the three-part pharmacokinetics bridging study conducted ahead of a Phase 3 registration trial in autosomal dominant polycystic kidney disease (“ADPKD”), a rare disease that affects more than 10M globally. According to topline data, two versions of XORTX’s (XRTX) oxypurinol formulation was found to have a substantial increase in oral bioavailability compared to a control, the company said. In addition, the oral administration of oxypurinol showed a clean safety and pharmacologic profile with no drug related adverse or serious adverse events, XORTX (XRTX) added. Last week, the company requested a type B Pre-Phase 3 meeting with the FDA, in connection with its clinical development of an ADPKD therapy.

CEO Compensation Analysis

How has Allen Davidoff's remuneration changed compared to XORTX Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$3m

Dec 31 2025US$330kUS$325k

-US$3m

Sep 30 2025n/an/a

-US$2m

Jun 30 2025n/an/a

-US$2m

Mar 31 2025n/an/a

-US$993k

Dec 31 2024US$417kUS$344k

-US$3m

Sep 30 2024n/an/a

-US$737k

Jun 30 2024n/an/a

-US$1m

Mar 31 2024n/an/a

-US$3m

Dec 31 2023US$322kUS$255k

-US$2m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$7m

Mar 31 2023n/an/a

-US$7m

Dec 31 2022US$321kUS$273k

-US$8m

Sep 30 2022n/an/a

US$1m

Jun 30 2022n/an/a

-US$3m

Mar 31 2022n/an/a

-US$2m

Jan 01 2022n/an/a

-US$2m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$204kUS$154k

-US$1m

Sep 30 2020n/an/a

-US$767k

Jun 30 2020n/an/a

-US$536k

Mar 31 2020n/an/a

-US$362k

Dec 31 2019US$161kUS$148k

-US$485k

Compensation vs Market: Allen's total compensation ($USD330.38K) is below average for companies of similar size in the US market ($USD658.93K).

Compensation vs Earnings: Allen's compensation has been consistent with company performance over the past year.

CEO

Allen Davidoff (66 yo)

8.5yrs
Tenure
US$330,378
Compensation

Dr. Allen Warren Davidoff, Ph.D. is Founder of XORTX Therapeutics Inc. (formerly known as XORTX Pharma Corp.) and has been its President since January 9, 2018 and as its Co-Chief Executive Officer from Jun...

Leadership Team

NamePositionTenureCompensationOwnership
Allen Davidoff
Founder8.5yrsUS$330.38k1.46%
$ 52.0k
Michael Bumby
Chief Financial Officer1.6yrsUS$167.31kno data
Stephen Haworth
Chief Medical Officer5yrsUS$98.59k0%
$ 0
Stacy Evans
Chief Business Officer3.7yrsUS$150.00kno data
Mika Grasso
Co-CEO & Directorless than a yearno datano data
Nick Rigopulos
Director of Communicationsno datano datano data
David Sans
Director of Corporate Development5.9yrsno datano data
David MacDonald
Consultant of Clinical Operations4.2yrsno datano data
Charlotte May
Corporate Secretaryno datano datano data
4.2yrs
Average Tenure
62yo
Average Age

Experienced Management: XRTX's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Allen Davidoff
Founder8.5yrsUS$330.38k1.46%
$ 52.0k
Mika Grasso
Co-CEO & Directorless than a yearno datano data
Anthony Giovinazzo
Independent Chair of the Board4.1yrsUS$124.98k0.11%
$ 4.0k
Richard Johnson
Member of Clinical Advisory Boardno datano datano data
George Scorsis
Directorless than a yearno datano data
Petter Bjornstad
Member of Clinical Advisory Board7.8yrsno datano data
Richard Grieve
Directorless than a yearno datano data
Anjay Rastogi
Member of the Clinical Advisory Board6.3yrsno datano data
Charles Edelstein
Member of the Advisory Board4.9yrsno datano data
Ronald Perrone
Member of Clinical Advisory Board2.3yrsno datano data
4.1yrs
Average Tenure
57.5yo
Average Age

Experienced Board: XRTX's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 09:32
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

XORTX Therapeutics Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners